Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes.
暂无分享,去创建一个
Hans Matter | Armin Bauer | Marc Nazaré | H. Matter | H. Schreuder | A. Bauer | M. Nazaré | M. Urmann | David W Will | Michael Wagner | Matthias Urmann | Jörg Czech | Herman Schreuder | Kurt Ritter | Volkmar Wehner | J. Czech | K. Ritter | D. W. Will | M. Wagner | V. Wehner
[1] F. Diederich,et al. Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions. , 2009, Angewandte Chemie.
[2] François Diederich,et al. Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. , 2005, Angewandte Chemie.
[3] D. A. Dougherty,et al. Cation-π interactions in structural biology , 1999 .
[4] S. Brady,et al. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. , 1998, Journal of medicinal chemistry.
[5] L. Salonen,et al. Kation‐π‐Wechselwirkungen im aktiven Zentrum von Faktor Xa: drastische Verstärkung durch stufenweise N‐Alkylierung von Ammoniumionen , 2009 .
[6] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[7] D. Banner,et al. Quantifizierung von Kation‐π‐Wechselwirkungen in Protein‐Ligand‐Komplexen: Kristallstrukturanalyse eines Komplexes von Faktor Xa und einem quartären Ammonium‐Ion‐Liganden , 2005 .
[8] Manfred Kansy,et al. Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series. , 2010, European journal of medicinal chemistry.
[9] Hans Matter,et al. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. , 2005, Journal of medicinal chemistry.
[10] A. Hillisch,et al. Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban). , 2010, Current topics in medicinal chemistry.
[11] Marcel L. Verdonk,et al. The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..
[12] Sébastien Maignan,et al. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. , 2003, Journal of medicinal chemistry.
[13] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[14] Kerim Babaoglu,et al. Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.
[15] Thomas Lampe,et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. , 2005, Journal of medicinal chemistry.
[16] W. Jencks,et al. Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[17] Wolfgang Heiden,et al. Fast generation of molecular surfaces from 3D data fields with an enhanced “marching cube” algorithm , 1993, J. Comput. Chem..
[18] Stefan Güssregen,et al. Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. , 2009, Angewandte Chemie.
[19] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[20] V. Mikol,et al. The use of 3D structural data in the design of specific factor Xa inhibitors. , 2001, Current topics in medicinal chemistry.
[21] W F van Gunsteren,et al. Decomposition of the free energy of a system in terms of specific interactions. Implications for theoretical and experimental studies. , 1994, Journal of molecular biology.
[22] Claudio Luchinat,et al. Entropic contribution to the linking coefficient in fragment based drug design: a case study. , 2010, Journal of medicinal chemistry.
[23] Bin Ye,et al. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. , 2002, Biochemistry.
[24] D. Cheney,et al. Factor Xa inhibitors: next-generation antithrombotic agents. , 2010, Journal of medicinal chemistry.
[25] Jing Zhang,et al. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors. , 2008, Journal of medicinal chemistry.
[26] Gennady M Verkhivker,et al. Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[27] T. Blundell,et al. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.
[28] Emanuele Perola,et al. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.
[29] P. Hajduk,et al. Stromelysin Inhibitors Designed from Weakly Bound Fragments: Effects of Linking and Cooperativity , 1997 .
[30] G. Klebe,et al. pH‐Dependent Binding Modes Observed in Trypsin Crystals: Lessons for Structure‐Based Drug Design , 2002 .
[31] C. Abad-Zapatero,et al. Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.
[32] Colin McMartin,et al. QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..
[33] Beat Ernst,et al. Drug discovery today. , 2003, Current topics in medicinal chemistry.
[34] Hans Matter,et al. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. , 2005, Journal of medicinal chemistry.
[35] K A Dill,et al. Additivity Principles in Biochemistry* , 1997, The Journal of Biological Chemistry.
[36] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[37] Daniel A Erlanson,et al. Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.
[38] H. Matter,et al. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand. , 2004, Bioorganic & medicinal chemistry letters.
[39] Christopher W Murray,et al. Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.
[40] Gerhard Klebe,et al. Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry. , 2010, Journal of molecular biology.
[41] S. Barelier,et al. Fragment-based deconstruction of Bcl-xL inhibitors. , 2010, Journal of medicinal chemistry.
[42] Loriano Storchi,et al. New and Original pKa Prediction Method Using Grid Molecular Interaction Fields , 2007, J. Chem. Inf. Model..
[43] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.